To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure email@example.com
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This chapter discusses the symptoms that occur repeatedly in association with the menstrual cycle and during the menopause transition (MT). Several studies have refuted the hypothesis that premenstrual syndrome (PMS)/premenstrual dysphoric disorder (PMDD) is associated with abnormalities in circulating ovarian hormones. Antidepressant medications with primary serotonergic action, such as the selective serotonin reuptake inhibitors (SSRIs), have become the mainstay of pharmacological treatment of PMDD, with proven safety and efficacy. Given that women with PMDD are more sensitive to the normal hormonal fluctuations of the menstrual cycle, several trials have been conducted to examine whether manipulation of the female sex hormones could lead to an effective treatment of PMDD. Prospective studies have consistently shown that during MT women are at higher risk to develop depressive symptoms and/or to meet criteria for major depressive disorder (MDD). Antidepressants remain the first choice for the management of depression in any given age/reproductive staging group.